OC-1016(OC-1016) - _专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点-

作用机制-

治疗领域

口颌疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

骨病牙疾病

原研机构

The Children's Hospital Corp.

在研机构-

非在研机构

OraPharma, Inc.

The Children's Hospital Corp.

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 OC-1016 相关的临床结果

登录后查看更多信息

100 项与 OC-1016 相关的转化医学

登录后查看更多信息

100 项与 OC-1016 相关的专利（医药）

登录后查看更多信息

1

项与 OC-1016 相关的文献（医药）

2016-11-01·The International Journal of Periodontics & Restorative Dentistry4区 · 医学

The Effect of Osteopontin and an Osteopontin-Derived Synthetic Peptide Coating on Osseointegration of Implants in a Canine Model

4区 · 医学

Article

作者: Sven Glindmann ; Jairo Salcedo ; Hans Peter Weber ; Joseph P. Fiorellini ; Hector L. Sarmiento ; Chang Joo Park

Osteopontin (OPN) and an OPN-derived synthetic peptide, OC-1016, have demonstrated their potential to enhance osseointegration in vitro. The purpose of this study was to evaluate bone-to-implant contact (BIC) and surrounding bone density (BD) of implants coated with either recombinant human OPN (rhOPN) or OC-1016 as compared with noncoated titanium plasma sprayed (TPS) surface in a canine model. Histomorphometric analysis revealed that at 4 weeks, %BIC and %BD of coated implants were significantly higher than those of noncoated TPS implants. At 12 weeks, %BIC of coated implants was also significantly higher than that of noncoated implants; however, there was no statistically significant difference in %BD. The rhOPN and OC-1016 were concluded to be capable of significantly accelerating the early stage of osseointegration and bone healing around implants.

100 项与 OC-1016 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨病	药物发现	美国	OraPharma, Inc.	-
骨病	药物发现	美国	The Children's Hospital Corp.	-
牙疾病	药物发现	美国	OraPharma, Inc.	-
牙疾病	药物发现	美国	The Children's Hospital Corp.	-